Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NHL)

NCT05365659 is registered in ClinicalTrials.gov with Iksuda Therapeutics Ltd. as lead sponsor.

NCT NCT05365659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05365659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NHL)
Lead sponsor
Iksuda Therapeutics Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 5, 2023
Completion date
September 30, 2028
Enrollment
140 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, b-cell non-hodgkin lymphoma, diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma